Cargando…
Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism
BACKGROUND: Serotonin reuptake inhibitors (SSRIs) are commonly prescribed off-label for children with autism. To date, clinical trials examining the use of SSRIs in autism have been limited by small sample sizes and inconclusive results. The efficacy and safety of SSRIs for moderating autistic behav...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067505/ https://www.ncbi.nlm.nih.gov/pubmed/24934401 http://dx.doi.org/10.1186/1745-6215-15-230 |
_version_ | 1782322300414066688 |
---|---|
author | Mouti, Anissa Reddihough, Dinah Marraffa, Catherine Hazell, Philip Wray, John Lee, Katherine Kohn, Michael |
author_facet | Mouti, Anissa Reddihough, Dinah Marraffa, Catherine Hazell, Philip Wray, John Lee, Katherine Kohn, Michael |
author_sort | Mouti, Anissa |
collection | PubMed |
description | BACKGROUND: Serotonin reuptake inhibitors (SSRIs) are commonly prescribed off-label for children with autism. To date, clinical trials examining the use of SSRIs in autism have been limited by small sample sizes and inconclusive results. The efficacy and safety of SSRIs for moderating autistic behaviors is yet to be adequately examined to provide evidence to support current clinical practice. The aim of the Fluoxetine for Autistic Behaviors (FAB) study is to determine the efficacy and safety of low dose fluoxetine compared with placebo, for reducing the frequency and severity of repetitive stereotypic behaviors in children and adolescents with an autism spectrum disorder (ASD). The relationship between the effectiveness of fluoxetine treatment and serotonin transporter genotype will also be explored. METHODS/DESIGN: The FAB study is a multicenter, double-blinded, randomized controlled trial, funded by the Australian Government’s National Health and Medical Research Council (NHMRC) grant. Participants will be aged between 7.5 and 17 years with a confirmed diagnosis of ASD. Eligible participants will be randomized to either placebo or fluoxetine for a 16-week period. Medication will be titrated over the first four weeks. Reponses to medication will be monitored fortnightly using the Clinical Global Impressions Scale (CGI). The primary outcome measure is the Children’s Yale-Brown Obsessive Compulsive Scale-Modified for Pervasive Developmental Disorders (CYBOCS-PDD), administered at baseline and 16 weeks. Secondary outcome measures include the Aberrant Behaviour Scale (ABC), the Spence Children’s Anxiety Scale Parent Report (SCAS-P), and the Repetitive Behaviors Scale (RBS-R), measured at baseline and 16 weeks. Participants will be invited to undergo genetic testing for SLC6A4 allele variants using a cheek swab. Continuous outcomes, including the primary outcome will be compared between the active and placebo groups using unadjusted linear regression. Binary outcomes will be compared using unadjusted logistic regression. DISCUSSION: The FAB study is a large clinical trial to specifically investigate the efficacy of low dose fluoxetine for restricted, repetitive, and stereotyped behaviors in ASD. The outcomes of this study will contribute to evidence-based interventions used in clinical practice to assist children with ASD. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry ACTRN12608000173392; registered on 9 April, 2008. |
format | Online Article Text |
id | pubmed-4067505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40675052014-06-25 Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism Mouti, Anissa Reddihough, Dinah Marraffa, Catherine Hazell, Philip Wray, John Lee, Katherine Kohn, Michael Trials Study Protocol BACKGROUND: Serotonin reuptake inhibitors (SSRIs) are commonly prescribed off-label for children with autism. To date, clinical trials examining the use of SSRIs in autism have been limited by small sample sizes and inconclusive results. The efficacy and safety of SSRIs for moderating autistic behaviors is yet to be adequately examined to provide evidence to support current clinical practice. The aim of the Fluoxetine for Autistic Behaviors (FAB) study is to determine the efficacy and safety of low dose fluoxetine compared with placebo, for reducing the frequency and severity of repetitive stereotypic behaviors in children and adolescents with an autism spectrum disorder (ASD). The relationship between the effectiveness of fluoxetine treatment and serotonin transporter genotype will also be explored. METHODS/DESIGN: The FAB study is a multicenter, double-blinded, randomized controlled trial, funded by the Australian Government’s National Health and Medical Research Council (NHMRC) grant. Participants will be aged between 7.5 and 17 years with a confirmed diagnosis of ASD. Eligible participants will be randomized to either placebo or fluoxetine for a 16-week period. Medication will be titrated over the first four weeks. Reponses to medication will be monitored fortnightly using the Clinical Global Impressions Scale (CGI). The primary outcome measure is the Children’s Yale-Brown Obsessive Compulsive Scale-Modified for Pervasive Developmental Disorders (CYBOCS-PDD), administered at baseline and 16 weeks. Secondary outcome measures include the Aberrant Behaviour Scale (ABC), the Spence Children’s Anxiety Scale Parent Report (SCAS-P), and the Repetitive Behaviors Scale (RBS-R), measured at baseline and 16 weeks. Participants will be invited to undergo genetic testing for SLC6A4 allele variants using a cheek swab. Continuous outcomes, including the primary outcome will be compared between the active and placebo groups using unadjusted linear regression. Binary outcomes will be compared using unadjusted logistic regression. DISCUSSION: The FAB study is a large clinical trial to specifically investigate the efficacy of low dose fluoxetine for restricted, repetitive, and stereotyped behaviors in ASD. The outcomes of this study will contribute to evidence-based interventions used in clinical practice to assist children with ASD. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry ACTRN12608000173392; registered on 9 April, 2008. BioMed Central 2014-06-16 /pmc/articles/PMC4067505/ /pubmed/24934401 http://dx.doi.org/10.1186/1745-6215-15-230 Text en Copyright © 2014 Mouti et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Mouti, Anissa Reddihough, Dinah Marraffa, Catherine Hazell, Philip Wray, John Lee, Katherine Kohn, Michael Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism |
title | Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism |
title_full | Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism |
title_fullStr | Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism |
title_full_unstemmed | Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism |
title_short | Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism |
title_sort | fluoxetine for autistic behaviors (fab trial): study protocol for a randomized controlled trial in children and adolescents with autism |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067505/ https://www.ncbi.nlm.nih.gov/pubmed/24934401 http://dx.doi.org/10.1186/1745-6215-15-230 |
work_keys_str_mv | AT moutianissa fluoxetineforautisticbehaviorsfabtrialstudyprotocolforarandomizedcontrolledtrialinchildrenandadolescentswithautism AT reddihoughdinah fluoxetineforautisticbehaviorsfabtrialstudyprotocolforarandomizedcontrolledtrialinchildrenandadolescentswithautism AT marraffacatherine fluoxetineforautisticbehaviorsfabtrialstudyprotocolforarandomizedcontrolledtrialinchildrenandadolescentswithautism AT hazellphilip fluoxetineforautisticbehaviorsfabtrialstudyprotocolforarandomizedcontrolledtrialinchildrenandadolescentswithautism AT wrayjohn fluoxetineforautisticbehaviorsfabtrialstudyprotocolforarandomizedcontrolledtrialinchildrenandadolescentswithautism AT leekatherine fluoxetineforautisticbehaviorsfabtrialstudyprotocolforarandomizedcontrolledtrialinchildrenandadolescentswithautism AT kohnmichael fluoxetineforautisticbehaviorsfabtrialstudyprotocolforarandomizedcontrolledtrialinchildrenandadolescentswithautism |